Effect of the specific proteasome inhibitor bortezomib on cancer-related muscle wasting.

ABSTRACT:

Background

Muscle wasting, a prominent feature of cancer cachexia, is mainly caused by sustained protein hypercatabolism. The enhanced muscle protein degradation rates rely on the activity of different proteolytic systems, although the Adenosine triphosphate (ATP)-ubiquitin-proteasome-dependent pathway and autophagy have been shown to play a pivotal role. Bortezomib is a potent reversible and selective proteasome and NF-κB inhibitor approved for the clinical use, which has been shown to be effective in preventing muscle wasting in different catabolic conditions. The aim of the present study has been to investigate whether pharmacological inhibition of proteasome by bortezomib may prevent skeletal muscle wasting in experimental cancer cachexia.

Methods

Cancer cachexia was ind

SUBMITTER: Penna F 

PROVIDER: S-EPMC4864285 | biostudies-literature | 2016 Jun

REPOSITORIES: biostudies-literature